Caring Brands, Inc. 8-K
Research Summary
AI-generated summary
Caring Brands, Inc. Denied Nasdaq Continued Listing; Hearing Planned
What Happened
Caring Brands, Inc. (CABR) reported that on July 15, 2026 Nasdaq’s Listing Qualifications Staff issued a Staff Delisting Determination denying the Company’s request to remain listed on The Nasdaq Capital Market for failure to meet Nasdaq Listing Rule 5550(b). Nasdaq first notified the Company on April 7, 2026 that CABR’s stockholders’ equity was $2,091,324—below the $2.5 million minimum—and the Company also failed to meet the alternative continued listing standards (a $35 million market value of listed securities or $500,000 net income). The Company intends to request a hearing before a Nasdaq Hearings Panel (and to pay the applicable fee) by July 21, 2026; a timely hearing request will stay any suspension and allow the common stock to continue trading while the Panel considers the appeal.
Key Details
- Stockholders’ equity reported: $2,091,324 (below $2.5M required under Nasdaq Rule 5550(b)).
- Nasdaq Determination date: July 15, 2026; initial noncompliance notice: April 7, 2026.
- Alternatives not met: market value of listed securities < $35M and net income < $500,000 (in required periods).
- Company’s proposed compliance measures included amending terms of its Series A Convertible Redeemable Preferred Stock and obtaining additional financing from the PIPE investor; Nasdaq found no definitive financing agreement and rejected the Company’s plan.
- If no timely hearing request, trading would be suspended at the opening of business on July 24, 2026 and Nasdaq would file Form 25‑NSE with the SEC.
Why It Matters
A delisting determination signals a material listing risk. If Nasdaq’s suspension were to occur (absent a successful hearing or plan to regain compliance), CABR’s common stock could be removed from The Nasdaq Capital Market, reducing liquidity and potentially narrowing investor access. The Company has taken the immediate step of seeking a hearing to contest the Determination, but the outcome is uncertain and depends on the Panel’s decision and the Company’s ability to secure definitive financing or otherwise meet Nasdaq requirements.
Loading document...